You can buy or sell Varian and other stocks, options, ETFs, and crypto commission-free!
Varian Medical Systems, Inc. engages in the manufacture of medical devices and software for treating cancer and other medical conditions. It operates through the Oncology Systems and Proton Solutions segments. Read More The Oncology Systems segment designs, manufactures, sells, and services hardware and software products for treating cancer with conventional radiation therapy, and advanced treatments. The Proton Solutions segment delivers proton therapy, a form of external beam radiotherapy using proton beams for the treatment of cancer. The company was founded by William Hansen, Edward Ginzton, Russell Varian, and Sigurd Varian in 1948 and is headquartered in Palo Alto, CA.
Palo Alto, California
52 Week High
52 Week Low
Varian Medical Systems To Acquire Cancer Treatment Services For India Cancer Data
With the deal, VAR is gaining direct access to patient treatment data which it will use to inform its cancer product development.
Yahoo FinanceMay 21
Varian Medical's CTSI Buyout to Boost Oncology Services Unit
Varian Medical Systems, Inc. VAR recently entered into a definitive agreement to acquire Cancer Treatment Services International (“CTSI”) for $283 million. The collaboration is expected to boost Varian Medical’s core Oncology Systems business. More on the Deal Varian Medical expects the deal to have a 6-cent-per-share-dilutive impact on earnings on a reported basis and 3 cents on an adjusted basis. Varian Medical also expects the buyout to be accretive to earnings per share during fiscal 2021 on an adjust...
Seeking AlphaMay 20
Varian Medical scoops up CTSI for $283M
Varian Medical Systems agrees to acquire privately held Cancer Treatment Services International or CTSI for $283M. The transaction is expected to increase Varian's expertise in cancer center operations, as well as expand the scope and geographic reach of CTSI's technology-enabled clinical solutions. CTSI generated annual revenues of $43.5M and Varian expects the acquisition to be accretive to EPS in FY2021 on non-GAAP basis and FY2022 on GAAP basis. VAR is adjusting its FY19 annual guidance given the pro...
Expected Jul 24, After Hours